European Central Bank: Digital Euro Will Enhance Payment Security and Inclusiveness
ChainCatcher reported that Piero Cipollone, a member of the Executive Board of the European Central Bank, stated at the European Parliament's Committee on Economic and Monetary Affairs that the digital euro will strengthen Europe's defense capabilities against network and infrastructure disruptions, while ensuring broad accessibility to digital payments.
Cipollone pointed out that Europe's reliance on foreign payment service providers exposes citizens to risks during times of crisis. The digital euro will provide "backup capacity" for the financial system by adding a public payment channel in addition to private solutions. Planned security measures include cross-regional transaction processing, a mandatory European Central Bank-operated application, and offline payment functionality.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
